Concourse Financial Group Securities, Inc. Minerva Neurosciences, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.52 Billion
Q1 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$2.5 - $12.47 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	BUY	$3.96 - $7.85 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$6.9 - $13.05 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$6.9 - $13.05 $0 - $0	0 New	0 $0
Q2 2023 Aug 10, 2023	BUY	$1.62 - $10.19 $0 - $0	0 New	0 $0

Q1 2023 May 15, 2023	BUY	$1.51 - $3.09 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$1.43 - $3.88 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$2.53 - $13.17 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$2.7 - $7.68 $0 - $0	0 New	0 $0

Others Institutions Holding NERV

# of Institutions

Shares Held

2.1M

Call Options Held

Put Options Held

View Full List

About Minerva Neurosciences, Inc.

Ticker NERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,340,190
Market Cap $16.8M
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...

More about NERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account